Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

4.8%

1 terminated/withdrawn out of 21 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

71%

15 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 4
11(61.1%)
Phase 3
4(22.2%)
N/A
2(11.1%)
Phase 1
1(5.6%)
18Total
Phase 4(11)
Phase 3(4)
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT07451665Phase 4Not Yet Recruiting

Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

Role: lead

NCT07381465Phase 4Not Yet Recruiting

Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus

Role: lead

NCT04582136Phase 3Active Not Recruiting

Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus

Role: lead

NCT06881290Phase 1Recruiting

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

Role: lead

NCT07013838Phase 4Not Yet Recruiting

The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

Role: lead

NCT07008196Phase 4Not Yet Recruiting

Telitacicept for the Treatment of Refractory RA

Role: lead

NCT06887517Recruiting

Chinese Rheumatism Biobank(CRB)

Role: lead

NCT05916781Phase 4Recruiting

Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus

Role: lead

NCT06385093Phase 4Not Yet Recruiting

A Study on the Prevention and Treatment of GIOP With Eldecalcitol

Role: lead

NCT05828147Phase 4Recruiting

Anti-CD20 Antibodies for Treatment of SLE-PAH

Role: lead

NCT06167174Recruiting

Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis

Role: lead

NCT03483597Completed

The Survey of Satisfaction in Chinese Rheumatologists and Patients With Rheumatoid Arthritis

Role: lead

NCT05805891Not ApplicableUnknown

Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

Role: lead

NCT03096275Phase 3Completed

Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis

Role: lead

NCT05965284Phase 4Recruiting

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

Role: lead

NCT05962840Phase 4Recruiting

Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

Role: lead

NCT05151848Phase 4Unknown

Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

Role: lead

NCT05749666Phase 3Unknown

Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis

Role: lead

NCT02444728Phase 3Terminated

Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE

Role: lead

NCT04737343Not ApplicableUnknown

Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis

Role: lead